We investigated whether fenofibrate, metformin, and their combination generate cardioprotection in a rat model of type 2 diabetes (T2D) and acute myocardial infarction (AMI). Streptozotocin-induced diabetic- (DB-) rats received 14 days of either vehicle, fenofibrate, metformin, or their combination and immediately after underwent myocardial ischemia/reperfusion (I/R). Fenofibrate plus metformin generated cardioprotection in a DBI/R model, reported as decreased coronary vascular resistance, compared to DBI/R-Vehicle, smaller infarct size, and increased cardiac work. The subchronic treatment with fenofibrate plus metformin increased, compared with DBI/R-Vehicle, total antioxidant capacity, manganese-dependent superoxide dismutase activity (MnSOD), guanosine triphosphate cyclohydrolase I (GTPCH-I) expression, tetrahydrobiopterin : dihydrobiopterin (BH4 : BH2) ratio, endothelial nitric oxide synthase (eNOS) activity, nitric oxide (NO) bioavailability, and decreased inducible NOS (iNOS) activity. These findings suggest that PPARαactivation by fenofibrate + metformin, at low doses, generates cardioprotection in a rat model of T2D and AMI and may represent a novel treatment strategy to limit I/R injury in patients with T2D.
The purpose of the present study was to analyze the actions of transient receptor potential vanilloid type 1 (TRPV1) agonist capsaicin (CS) and of its antagonist capsazepine (CZ), on cardiac function as well as endothelial biomarkers and some parameters related with nitric oxide (NO) release in L-NG-nitroarginine methyl ester (L-NAME)-induced hypertensive rats. NO has been implicated in the pathophysiology of systemic arterial hypertension (SAHT). We analyzed the levels of nitric oxide (NO), tetrahydrobiopterin (BH4), malondialdehyde (MDA), total antioxidant capacity (TAC), cyclic guanosin monophosphate (cGMP), phosphodiesterase-3 (PDE-3), and the expression of endothelial nitric oxide synthase (eNOS), guanosine triphosphate cyclohydrolase 1 (GTPCH-1), protein kinase B (AKT), and TRPV1 in serum and cardiac tissue of normotensive (118±3 mmHg) and hypertensive (H) rats (165 ± 4 mmHg). Cardiac mechanical performance (CMP) was calculated and NO was quantified in the coronary effluent in the Langendorff isolated heart model. In hypertensive rats capsaicin increased the levels of NO, BH4, cGMP, and TAC, and reduced PDE-3 and MDA. Expressions of eNOS, GTPCH-1, and TRPV1 were increased, while AKT was decreased. Capsazepine diminished these effects. In the hypertensive heart, CMP improved with the CS treatment. In conclusion, the activation of TRPV1 in H rats may be an alternative mechanism for the improvement of cardiac function and systemic levels of biomarkers related to the bioavailability of NO.
Lychee is a fruit of Asian origin with an exquisite flavor and an attractive reddish color. However, according to recent reports, the consumption of this fruit reduces the levels of blood glucose with adverse effects on human health such as encephalopathy and hypoglycemic. The objective of this work was to determine if the peel, pulp, and seed of “Brewster” lychee fruits harvested at two stages of maturity had antihyperglycemic effect. This effect was determined by an oral glucose tolerance test using Wistar rats. In addition, ultraviolet-visible spectrophotometry and high-resolution liquid chromatography were used to quantify phenolic compounds, flavonoids, organic acids (OAs), sugars, and antioxidant activity. Results indicated that stage I pulp (immature fruits) and stage II peel and seed (export mature fruits) reduced blood glucose levels, and the effects of the former two were synergistic with metformin. The pulp of mature fruits (stage II), however, lacked a hypoglycemic effect. Additionally, the peel and the seeds of these fruits presented a high antioxidant activity (as determined by DPPH [2,2-diphenyl-2-picryl-hydracyl] and ABTS + [2,2-azino-bis-(3-ethylbenzothiazoline)-6-sulfonic acid] methods), which correlated well with the total content of phenolic compounds. The highest content of polyphenolics, flavonoids, and OAs was found in the extracts of the peel and seeds of both stages of maturity. It was therefore concluded that “Brewster” mature lychees are safe for human consumption, and both the seed and the peel can be useful sources for obtaining new compounds with antihyperglycemic activity.